Law360, New York (September 06, 2012, 7:34 PM ET) -- The U.S. Food and Drug Administration gets new cancer medicines to patients more rapidly than other pharmaceuticals, and the opposite is true for the European Medicines Agency, according to a study published Wednesday that adds to a growing collection of data comparing the two agencies.
The Tufts Center for the Study of Drug Development in Massachusetts examined approvals over the past decade and found that American regulators cleared oncology treatments 10 months quicker than non-oncology pharmaceuticals. On the other hand, the EMA brought cancer drugs to...
FDA Beats EU On Cancer Drugs, But Not Others, Study Shows
To view the full article, take a free trial now.
